Latest market price
230.50
+0.75+0.33%
DHRQT61Danaher Corporation·NYSE
230.50+0.33%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E37.73EPS (ttm)6.11Insider Own1.03%Shs Outstand702.99MPerf Week0.64%
Market Cap162.04BForward P/E24.74EPS next Y9.32Insider Trans-0.83%Shs Float626.27MPerf Month3.01%
Enterprise Value182.84BPEG4.37EPS next Q-Inst Own77.39%Short Float1.43%Perf Quarter17.30%
Income4.33BP/S6.33EPS this Y10.76%Inst Trans0.00%Short Ratio1.91Perf Half Y30.04%
Sales25.61BP/B3.02EPS next Y8.76%ROA4.64%Short Interest8.97MPerf YTD0.69%
Book/sh76.29P/C28.52EPS next 5Y9.37%ROE8.18%52W High242.81 -5.07%Perf Year5.69%
Cash/sh8.08P/FCF28.29EPS past 3/5Y-19.44% 0.61%ROIC5.43%52W Low160.93 43.23%Perf 3Y12.55%
Dividend Est.1.60 (0.69%)EV/EBITDA25.80Sales past 3/5Y-2.67% 1.97%Gross Margin58.59%Volatility3.89% 3.02%Perf 5Y-13.72%
Dividend TTM1.52 (0.66%)EV/Sales7.14EPS Y/Y TTM15.50%Oper. Margin20.38%ATR (14)6.92Perf 10Y241.23%
Dividend Ex-DateSep 30, 2026Quick Ratio1.29Sales Y/Y TTM7.26%Profit Margin16.91%RSI (14)59.86Recom2.28
Dividend Gr. 3/5Y13.02% 14.93%Current Ratio1.63EPS Q/Q11.64%SMA203.24%Beta0.77Target Price238.77
Payout23.46%Debt/Eq0.35Sales Q/Q8.28%SMA506.65%Rel Volume0.92Prev Close229.75
Employees59,000LT Debt/Eq0.35EarningsJan 27SMA20014.56%Avg Volume4.27MPrice230.50
IPO DateDec 29, 1978Option/ShortYes / YesEPS/Sales Surpr.10.05% -0.09%Net Debt/EBITDA2.94Volume3,935,380Change0.33%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-22-26ReiteratedUBSBuy$250 → $260
Oct-22-26ReiteratedGoldman SachsBuy$250 → $275
Oct-22-26ReiteratedRobert W. Baird$246 → $254
Oct-22-26ReiteratedBarclaysOverweight$230 → $260
Oct-05-26ReiteratedRBC CapitalOutperform$215 → $250
Oct-01-26ReiteratedGuggenheimBuy$200 → $250
Sep-09-26ReiteratedUBSBuy$240 → $250
Jul-22-26ReiteratedDeutsche BankBuy$250 → $240
Jul-22-26ReiteratedStifel NicolausHold$260 → $220
Jul-22-26ReiteratedWells FargoEqual Weight$240 → $195
Latest News· Times ET
Oct-22-26
Oct-21-26
Oct-19-26
Company

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Ownership
Total institutional ownership77.39%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue25,60824,56823,875——————
Cost of Goods Sold Incl. D&A10,6039,5989,669——————
Gross Profit15,00514,97014,206——————
Selling, General and Administrative Excl. Other8,1178,2357,438——————
Research and Development1,6701,5981,584——————
Other Operating Expense
000——————
Operating Income5,2185,1375,184——————
Interest Expense146265278——————
Unusual Expense
—————————
Non-Operating Income (Expense)-254-639-260——————
Net Income Before Taxes4,8184,2334,646——————
Income Taxes487619747——————
Consolidated Net Income4,3313,6143,899——————
Net Income From Continuing Operations4,3313,6143,899——————
Net Income4,3313,6143,899——————
EPS (Recurring)6.125.075.33——————
EPS (Basic, Before Extraordinaries)6.125.075.33——————
EPS (Diluted)6.115.045.29——————
EBITDA7,0876,9457,276——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio37.7345.4243.39——————
Price To Sales Ratio6.346.597.03——————
Gross Margin58.5960.9359.50——————
Operating Margin20.3820.9121.71——————
Net Margin16.9114.7116.33——————
Shares Outstanding704707731——————
Market Capitalization162,272161,846167,801——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$254.07$228.03$201.98$175.93$149.89● Close Price0.00M32.41M64.82M97.23M129.64MUSD Trades VolumeOctNovDec2026FebMarAprMayJunJulAugSepOct
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Blair RainerPresident & CEOAug 21 '26Sale218.6358,25512,736,0950Aug 24
FILLER LINDADirectorJul 15 '26Option Exercise71.883,298237,06028,010Jul 16
Zerhouni Elias A.DirectorJul 15 '26Option Exercise71.883,298237,06046,484Jul 16
SPOON ALAN GDirectorMay 01 '26Sale174.671,358237,207124,094May 04
SPOON ALAN GDirectorMay 01 '26Option Exercise71.883,298237,060125,452May 04
Milosevich Gregory MExecutive Vice PresidentFeb 19 '26Option Exercise58.591,32077,3396,419Feb 20
Milosevich Gregory MExecutive Vice PresidentFeb 19 '26Sale208.011,320274,5755,099Feb 20
RALES MITCHELL PChairman of Exec. CommitteeNov 25 '25Sale230.3840,6259,359,067850,000Nov 26
List TeriDirectorNov 18 '25Option Exercise71.883,298237,06024,060Nov 19
List TeriDirectorNov 18 '25Sale226.503,298746,99720,762Nov 19
RALES MITCHELL PChairman of Exec. CommitteeNov 12 '25Sale218.69437,00095,566,166553,228Nov 13
Ellis Brian WSenior Vice President - GCNov 12 '25Option Exercise58.5921,7761,275,85629,220Nov 13
Ellis Brian WSenior Vice President - GCNov 12 '25Sale219.2321,7764,773,86314,553Nov 13
McGrew MatthewEVP & Chief Financial OfficerNov 11 '25Sale214.6216,1723,470,83120,062Nov 13
McGrew MatthewEVP & Chief Financial OfficerNov 11 '25Option Exercise62.8516,1721,016,41036,234Nov 13
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.